Sitc 2025 Ak132. Presented at SITC 2023 Streamlining Tcell engager development AbCellera The SITC Spring Scientific, Cellular Therapy for Solid Tumors, will address the recent advances in adoptive cellular therapy for solid tumors and rate-limiti. Most importantly, AK132 neither bound to RBCs nor had ADCC or ADCP effects on RBCs
Home SITC 2025 from www.sitcancer.org
(Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking place March 12-14, 2025, in San Diego, C.A. AK132 showed ADCC, ADCP or CDC activity on CD47 + CLDN18.2+ tumor cells when compared with AK117
Home SITC 2025
8, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November 6 - 10, Akeso Biopharma (9926.HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, targeting both Claudin18.2 (CLDN18.2) and CD47. 8, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November 6 - 10, Akeso Biopharma (9926.HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, targeting both Claudin18.2 (CLDN18.2) and CD47. SITC 2025 is held in Washington DC, United States, from 11/5/2025 to 11/5/2025 in Gaylord National Resort and Convention Center.
Home SITC 2025. A similar approach is being pursued by Akeso, which in addition to the MAb ligufalimab recently took into phase 1 AK132, an anti-Claudin18.2 x CD47 MAb (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking place March 12-14, 2025, in San Diego, C.A.
Sitc 2025 Meeting Audi Koressa. And it's worth remembering Shattuck Labs, whose own take on CD47 differs by the inclusion of a CD40L domain to activate macrophages; further data from early trials of SL-154 are due this year. 8, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November 6 - 10, Akeso Biopharma (9926.HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, targeting both Claudin18.2 (CLDN18.2) and CD47.